Home and various

  • International Calendar - Test
  • EAACI General Assembly
    EAACI members are invited to the 2016 EAACI General Assembly that will take place during the EAACI Congress 2016 in Vienna, on Monday 13 June, 08:00-09:00am, at the Messe Vienna Exhibition & Congress Center in Hall A2.

    The 2016 Congress theme, “Waltzing with Allergens”, calls on all attendees to play a role in the Congress “Ball”, empowering them to create their own Congress – and to also take part in the creation and growth of their Academy. The General Assembly is an opportunity to be informed about current activities and future plans and actively participate in the life of the Academy. EAACI needs your input!

    Please download the agenda here.
    Last updated: 23 August 2016
  • EAACI 2016: There's an App for that!
    What you gain:
    Regular updates to the scientific programme,
    Practical information about the venue,
    Share your opinion and vote during dedicated sessions
    Access all abstracts and e-Posters as of Saturday 11 June 2016.

    Find exhibitors easily … and much more

    Download now in the Apple & Google store.
    Last updated: 23 August 2016
  • Symposium on Precision Medicine in Allergy and Asthma - Monday 13, 15.45-17.15
    The PRACTALL programme is an initiative of EAACI and AAAAI. It focuses on practical aspects of allergy to deliver updated and evidence based recommendations for clinicians
    In the light of the latest PRACTALL you are invited to join a symposium on Precision Medicine in Allergy and Asthma in Vienna exploring the latest findings in precisely defining the endotypic profile of the patient with allergic and/or asthmatic patient, and the potential for the specialty of allergy/immunology to utilize the precision medicine approach.
    Last updated: 23 August 2016
  • FAAM 2016: Join us in Rome!
    The registration and abstract submission for the 4th Food Allergy and Anaphylaxis Meeting, FAAM 2016, is open! The meeting will be hosted in Rome, Italy, 13 - 15 October 2016.

    FAAM will include a strong presence of all stakeholders in food allergy besides allergists such as pediatricians, gastroenterologists, food technologists, allied health, policy makers and patient’s organisations.

    The meeting will also provide opportunities for exchange of ideas and sharing of cutting edge science.
    Learn more.
    Last updated: 23 August 2016
  • EuroBAT 2016: Abstract submission extended until 28 August 2016
    The abstract submission deadline has been extended to Sunday 28 August 2016 at 24:00 CET. Original laboratory research, clinical research and case presentations are equally welcome.

    Submit your abstract and be a presenter at the 9th EuroBAT Meeting. The meeting will be an opportunity to learn more about the Basophil Activation Test (BAT) in Diagnosis and Monitoring of Allergic Disease with a focus on food and drug allergy. The whole day is designed for you to be the protagonist and share with international experts your recent research in the field.

    There is also an opportunity to further extend your knowledge by attending the Postgraduate Course on BAT, or the full Food Allergy and Anaphylaxis Meeting FAAM 2016 which will be held at the same venue just after EuroBAT starting on Thursday 13 October.
    Read more
    Last updated: 23 August 2016
  • Unable to be there? Watch the livestreams from Vienna – each day we have a session ready for you
    Sunday 12 June, 8:30 – 10:00 - Plenary 1
    25 years of recombinant allergens: Pitfalls and benefits
    Monday 13 June, 15:45-17:15 - Symposium 34
    PRACTALL on precision medicine in allergy and asthma
    Tuesday 14 June, 15:30-17:00 - Symposium 51
    Today’s perspective on allergen immunotherapy
    14 June, 08:30-10:00 - Plenary 5
    Allergy: Cause or consequence of epithelial barrier dysfunction ?

    Click here to join our EAACI Sessions virtually!
    Last updated: 19 August 2016
  • Plenary Symposia in Vienna – Top Notch Science at Prime Time
    EAACI Annual Congress offers top-notch education and the most exciting updates from the world of basic science and clinical work.
    This year’s Plenary Symposia will again be the core of the Congress with leading international speakers speaking at “prime time” in the mornings.
    12.06.2016 –
    25 years of recombinant allergens: Pitfalls and benefits
    13.06.2016 –
    Neutrophils: Too long ignored in allergy, Treating allergy with biologicals
    14.06.2016 –
    Allergy: Cause or consequence of epithelial barrier dysfunction?
     AIT: When and how?      
    15.06.2016 –
    Wrapping up immunotherapy
    Last updated: 19 August 2016
  • Presenting an abstract in Vienna? It’s your time to shine and win a prize!
    The Annual Congress in Vienna will once again be a fantastic platform for researchers and clinicians from all over the world, Juniors and Seniors, to present their work. If you are the presenting author of and accepted abstract in an Oral Abstract Session, Poster Discussion Session, or in one of the many Thematic Poster Sessions, this is a great opportunity to get valuable feedback from senior faculty and peers and to network and benefit of the experience of others.
    And last but not least, the best presentation of each session qualifies for an abstract prize of EUR 200! This is yet another motivation to be spot-on when presenting your work.
    All abstract prize winners will be announced at the end of each day at the EAACI counter in the Entrance Hall.
    All presented abstracts will also be published in Allergy and in the EAACI Congress app.
    Last updated: 19 August 2016
  • ISAF 2016: Join us in Manchester!
    The registration and abstract submission for the 3rd International Severe Asthma Forum, ISAF 2016 is open! The meeting will be hosted in Manchester, UK, 17 – 19 November

    2016. ISAF 2016 will bring together scientists and clinicians, with a broad range of experience from junior scientists/doctors to key opinion leaders, at a focused meeting dedicated to all aspects of severe asthma. The programme will be interactive and designed to facilitate discussions and encourage scientific collaborations enabling the translation of emerging discoveries into clinical practice. Learn more.
    Last updated: 19 August 2016
  • EAACI Fellowships: 2017 applications about to open
    The application for the 2017 EAACI Fellowship will be open from 1 October to 31 December 2016 to all EAACI Junior Members.

    The EAACI Research Fellowship supports research and training, fosters the exchange of knowledge and techniques and the implementation of new techniques throughout European laboratories.
    The EAACI Clinical Fellowship aims to promote specialised clinical training in allergy and clinical immunology and to support the medical specialty of allergy and clinical immunology throughout Europe.

    We strongly encourage you to take this great opportunity to further your professional and personal development and apply for a 2017 EAACI Fellowship.
    Read more
    Last updated: 19 August 2016
  • Master Class on Translational Immunology in Allergic Diseases 2016 : Join us in Zurich!
    The registration for the Master Class on Translational Immunology in Allergic Diseases is open! The meeting will be hosted in Zurich, Switzerland, 21 - 22 October 2016.
    The Master Class targets specialised clinicians who want to know more about the link between clinical presentation and treatment options with biologics based on endotyping. State of the art training on novel therapies and current unmet needs in allergic disorders will be addressed. Finally, the Master Class offers an excellent platform for exchange of knowledge.
    Learn more.
    Last updated: 19 August 2016
  • EAACI Congress Scholarship foster Junior Members around the globe
    EAACI is highly committed to its Junior Members and wants to make sure that JM from all over Europe and the world can attend the Annual Congress. Every year 100 Congress Scholarships are grated to JM who have successfully submitted an abstract. The scholarships include a complimentary registration to the Congress, a travel allowance of maximum of EUR 500 and accommodation in a shared twin room during the Congress period.
    The Scientific Programme Committee takes great care in making a fair selection, taking into account both abstract quality, but also the country of origin.
    We congratulate all 2016 Scholarship winners and are looking forward to welcoming them to Vienna.
    Last updated: 19 August 2016
  • New Impact factors for Allergy and PAI
    The new impact factors for Allergy and PAI have set a new record for the EAACI journals.

    Congratulations to all the editorial team, authors, reviewers and readers who greatly contributed to this success.

    Authors across the globe are welcome to submit their papers in the prestigious EAACI journals, Allergy and PAI and thus join the leading scientific community in the field of Allergy and Clinical Immunology.
    Last updated: 19 August 2016
  • The European Parliament Interest Group on Allergy and Asthma presents “Allergy at the forefront of EU Chronic Diseases Policy: The road towards better prevention and management of Allergy in Europe”

    Tuesday 26 April 2016 – European Parliament, Brussels
    Hosts: MEP Pietikäinen, MEP Childers, MEP Borrelli

      The European Parliament Interest Group on Allergy and Asthma invites you to the Allergy Exhibition - Test Your Allergies 2016 at the European Parliament in Brussels. To view the draft agenda of the opening meeting and the event poster Click Here.
    Last updated: 19 August 2016
  • Master Class on Translational Immunology in Allergic Diseases
    The Immunology Section and the Biologicals Interest Group of EAACI will organise the first ever Master Class on Translational Immunology in Allergic Diseases. The Master Class will be held from 21 - 22 October 2016 in Zurich, Switzerland. Learn more and register.
    Last updated: 19 August 2016
  • JM Quizz – April edition online

    The JM Quizz series consists of several quizzes, one per month, and is made for EAACI Junior Members. The quiz tests the scientific knowledge along with other, EAACI-related information. Each quiz consists of 5 single or multiple-choice questions and the answers can be found in the EAACI website, or in any one of the Academy’s publications. The winners will be awarded with a Travel Grant for the EAACI Congress 2016.
    Learn more and try your knowledge!

    Last updated: 20 June 2016
  • EAACI JM Mentorship Programme 2016
    The EAACI Junior Members Working Group is honoured to offer the EAACI Juniors the opportunity to be mentored by a Senior EAACI member, as part of the JM ‪Mentorship Programme (MP). Please apply by April the 10th.‬‬‬ Read more.
    Last updated: 20 June 2016
  • 60 years of EAACI - on the road to prevention and healthy living
    In 2016 EAACI is celebrating 60 years of excellence in research and education in allergy prevention and healthy living. To mark the occasion EAACI is rolling out an informational campaign to its members, national and international health stakeholders and policymakers with the aim of reframing the current conversation: from disease as a burden towards the chance for a healthy life.
    The more expert voices are raised, the more likely it is that the message will be heard: allergies and asthma are preventable and controllable! Learn more about the EAACI 2016 Campaign.

    View the Policy Makers & Healthcare Professionals brochures.

    View the Campaign Video
    Last updated: 02 June 2016
  • Postgraduate Course in Allergy for Primary Care doctors
    The Postgraduate Course for Primary Care doctors is designed to reproduce real situations in a virtual and safe medical setting. Course participants will get to explore various decision points similar to during a regular consultation. The course will take place during the EAACI Congress on 11 June. It will be possible to take the course in both German and English and it will be CME accredited.
    Learn more and register.
    Last updated: 02 June 2016
  • EAACI Congress 2016, Vienna - Middle Registration Fee
    Register to the world's largest Allergy Congress together with the top researchers in the fields of Allergy and Clinical Immunology in Vienna,
    11-15 June. Learn more and register
    Last updated: 02 June 2016
  • The application for the EAACI/UEMS Exam is open!

    This year's Exam will take place prior to the EAACI Congress 2016, on Saturday 11 June from 11:00 to 14:00. The application will be open from 1 February - 1 April 2016. EAACI supports participants by access to various resources including a list of literature, exam sample questions, and an online self-assessment. Furthermore, UEMS offers additional financial support for eligible candidates. Learn more and access all the resources.

    Last updated: 02 June 2016
  • Under Contruction
    Under Contruction
    Last updated: 01 December 2014
  • 30 January - 2 February 2014, Poiana Brasov, Romania Photos
    {gallery}/photos/2014/WSBrasov{/gallery}
    Last updated: 06 October 2014
  • 12th EAACI Winter School on Basic Research in Allergy and Clinical Immunology
    30 January – 2 February 2014
    Poiana Brasov, Romania


    Food allergies: from allergen to intestinal inflammation

    Eva Untersmayr
    Department of Pathophysiology and Allergy Research
    Medical University of Vienna

    Celiac Disease:Food hypersensitivity coupled with autoimmunity
    Ludvig M. Sollid
    University of Oslo

    Macrophage polarized activation in development and resolution of the inflammatory response
    Massimo Locati
    University of Milan
    Istituto Clinico Humanitas IRCCS

    Immune regulation in allergy and infection - the hygiene hypothesis in practice
    Rick Maizels
    University of Edinburgh, UK
    Last updated: 24 September 2014
  • EAACI Congress 2014, Copenhagen

    The EAACI Congress 2014 has been designated up to 24 hours of European CME credits (ECMEC). Take a look at the E-Preliminary Programme.
    The photo that number one in the rotating banner of http://www.eaaci2014.com/

    Last updated: 29 May 2014
  • Clinical Outcomes in SIT for RC
    “Recommendations for the Standardisation of Clinical Outcomes used in Allergen Immunotherapy (AIT) Trials for Allergic Rhinoconjunctivitis: an EAACI Position Paper” Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, Durham S, Jacobsen L, Malling HJ, Moesges R, Papadopoulos NG, Rak S, Rodriguez del Rio P, Valovirta E, Wahn U, Calderon MA

    Allergen immunotherapy (AIT) has been in clinical use for more than a century. Yet it is the only immune-modifying and causal treatment available for patients suffering from IgE-mediated diseases such as allergic rhinoconjunctivitis, allergic asthma and insect sting allergy. Many modifications of this ‘causal’ treatment including e.g., alternative routes of allergen application (sublingual AIT), innovative therapy protocols or the use of adjuvanted vaccines have been reported over the years. Evidence for the clinical efficacy and good tolerability of AIT has been found in many clinical studies and is thoroughly documented in randomised controlled trials (RCTs).

    However, there is a high degree of clinical and methodological heterogeneity among the (clinical) endpoints that have been used in clinical studies on AIT, for both subcutaneous and sublingual immunotherapy (SCIT and SLIT). At present, there are no commonly-accepted (by both regulators and academia) standards for defining the optimal outcome parameters to be used for both primary and secondary endpoints. The current EMA guideline states that, at present, no symptom scores or medication scores have been validated for clinical trials in AIT and that any proposed method must be scientifically justified. As a consequence, different manufacturers are using their (‘in-house’) endpoints to analyse clinical efficacy in the clinical documentation of their products.

    In order to increase the harmonisation of this definition, a Task Force (TF) of the EAACI Immunotherapy Interest Group, chaired by Oliver Pfaar (Germany), formed a paneuropean working group. The first achievement of this TF group was a thorough review of all (primary and secondary) endpoints which have so far been reported in clinical trials on AIT. Based on this work, the TF drafted a Position Paper (PP) highlighting the pro’s and con’s of each endpoint described in the trials and, furthermore, reported clear recommendations/unmet needs to improve the usage of the respective endpoint in future clinical trials of AIT. In this PP, the nine most relevant endpoints are reported. These nine ‘domains’ include i) Total Symptom Scores (TSS), ii) Medication Scores (MS), iii) Combined Symptom Medication Scores (CSMS), iv) Health-Related Quality of Life (HRQL), v) Visual Analogue Scale (VAS), vi) Well and Severe Days, vii) Global Assessments and Patient Satisfaction, viii) Rhinitis Control and ix) Allergen Provocation Tests.

    As the primary outcome, the TF recommends a homogeneous combined symptom and medication score (CSMS) as a simple and standardised method that balances both symptoms and the need for anti-allergic medication in an equally weighted manner (table 1). In principle, this composite score is based on and modified from the “Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases” by the European Medicines Agency (EMA) and a draft guidance document by the US Department of Health and Human Services Food and Drug Administration (FDA). Furthermore, this score considers standards addressed in a statement as proposed by the World Allergy Organization (WAO). The proposed terminology for the individual symptoms (dSS) in this score was elaborated with the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). The EAACI Position Paper recommends this standardised and harmonised CSMS as the primary endpoint for future clinical trials in AIT (mainly in pivotal phase III-trials).

    Acknowledgements: The Task Force was financed by EAACI. The authors would like to thank EAACI for their financial support in the development of this Task Force report and also Ms Anna Bedbrook for her assistance with the English language which was financed by a grant provided by EAACI.
    We warmly thank Prof. Dr. Stefan Vieths and Dr. Susanne Kaul (Paul Ehrlich Institut, Langen, Germany) for their helpful comments. We also thank Breda Flood and Susanna Palkonen from the European Federation of Allergy and Airways Diseases Patients' Asscociation (EFA) for their advice on the proposed terminology for the individual symptoms as well as for their review and fruitful comments on this document. Additionally, we thank Simon Lawton (ALK Abello, Hørsholm, Denmark) for his critical review and comments. Table: The Task Force recommendation providing (a) a homogeneous terminology for nasal and conjunctival symptoms using the six organ-related categories in the daily symptom score (dSS), (b) a stepwise use of rescue medication summed in the daily medication score (dMS) and (c) a scoring system for a combined symptom and medication score (CSMS), which is based on an equal weight of the dSS and of the dMS

    a) SYMPTOM SCORE
    Nasal Symptoms (SCORE 0 - 3) 0 = no symptoms 1 = mild symptoms (sign/symptom clearly present, but minimal awareness; easily tolerated) 2 = moderate symptoms (definite awareness of sign/symptom that is bothersome but tolerable) 3 = severe symptoms (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping)
    Itchy nose 0-3
    Sneezing 0-3
    Runny nose 0-3
    Blocked nose 0-3
     
    Conjunctival Symptoms Itchy/Red Eyes 0-3
    Watery Eyes 0-3
     
    (total) daily symptom score (dSS)* 0-3 (max score is 3, i.e. 18 points/ divided by 6 symptoms)
     
    b) MEDICATION SCORE
    Oral and/or topical (eyes or nose) non-sedative H1 antihistamines 1
    Intranasal corticosteroids 2
    Oral corticosteroids 3
     
    (total) daily medication score (dMS) 0-3 (max score is 3)
    c) COMBINED SYMPTOM AND MEDICATION SCORE
    CSMS dSS (0-3) + dMS (0-3) 0 -6


    * Max score 18/6 (i.e. 4 nasal symptoms, max score 12 and 2 conjunctival symptoms, max score 6) is optimal for studies of seasonal pollinosis. This could possibly be modified for studies of perennial allergies (e.g. in mite-allergic patients), for example max score 12/4 (i.e. 4 nasal symptoms with omission of eye symptoms). By assigning 0–3 for all individual symptoms and dividing by total number of symptoms, the symptom range 0–3 and maximum symptom score 3 would remain the same.

    Task Force background

    Coordinator: Oliver Pfaar

    Start date: 2011
    Finish date: 2013

    Participants: Hans Jorg Malling, Jörg Kleine Tebbe, Moises Calderon, Oliver Pfaar, Pablo Rodriguez del Rio, Pascal Demoly, Roy Gerth van Wijk and Sabina Rak. The expert panel review board will comprise Desire Larenas-Linnemann, Erkka Valovirta, Gianni Passalaqua, Jean Bousquet, Linda Cox, Ludger Klimek, Marek Jutel, Stephen Durham and Tom Casale.

    Rationale for establishing a Task Force: Specific subcutaneous immunotherapy (SCIT) and specific sublingual immunotherapy (SLIT) represent the only immune-modifying and causal treatments available for allergic patients. The evidence for the effects of SIT is based on controlled and randomized clinical trials using specific primary and secondary outcome measures (end points). Primary end points for evaluating clinical outcome are the severity of symptoms and the need for concomitant medication, and are usually obtained on a daily basis by keeping diaries. Secondary end points may include the specific and general (generic) quality of life (QoL) or impact on work-related abilities, and are usually obtained by questionnaires at follow-up. Some trials have also included allergen provocation tests, provocation chambers or other surrogate markers. However, there is a large and inevitable clinical and methodological heterogeneity on outcome parameter used amongst studies on both SLIT and SCIT. The different manufacturers have devised better or less validated outcome measures, which makes it difficult to compare or to perform metaanalyses of the clinical immunotherapy trials.In line with this, in the 2008 Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases the European Medicines Agency (EMA) states that to date, there are no symptoms scores thoroughly validated for clinical trials on SIT. However, for the evaluation of AR the 4 individual nasal symptoms “congestion,” “sneezing,” “itching,” and “secretion,” and 2 conjunctival symptoms “itching of eyes” and “ocular secretions,” are generally accepted. Shortness of breath, cough, wheezing, and chest tightness as concomitant lower airway symptoms are also considered in some clinical trials on SIT.Moreover, there is a complex and multifactorial connection between symptom scores and the use of concomitant medication. Therefore, it is recommended by the WAO-task force on SIT that symptom scores should always be combined with the concomitant medication scores to provide clinically more relevant information on SIT than assessing each of these two outcome parameters separately. This is achievable by a combined score (weighted sum scores of symptoms and rescue medications) or a symptom score adjusted for the use of medication, using a predefined algorithm. However, to date no standardized method for combined scores has been generally accepted. Taken together, generally accepted and authoritative national and international guidelines are still lacking with respect to the assessment of the therapeutic effects of SIT by using clearly defined symptom- and medication-scores. Therefore, the aim of the task-force would be to propose a position statement clearly defining how symptoms and medications should be assessed, analysed and weighted in prospective clinical trials on SLIT and SCIT

    Main objectives: To gather present scoring-systems used in trials on SLIT and SCIT to produce an EAACI position paper on the “optimal“ (primary) outcome parameters (combined SMS) recommended for clinical research.

    Outcomes and possible benefits to EAACI: Position statement on “EAACI-recommendation for outcome parameters in clinical trials on SIT” for SLIT and SCIT.

    Updates:First meeting of this Group: MADRID 10th and 11th of March, 2012. An intense meeting with an interesting discussion was held among the following attendees: Moises Calderon, Oliver Pfaar, Pablo Rodriguez del Rio, Pascal Demoly, and Roy Gerth van Wijk. In the first session Oliver Pfaar gave a lecture based on a review of current Clinical Outcomes used in SIT trials. During the rest of the session and in the second session each outcome was critically examined and the plan of action of the team, as well as possible involvement of other experts, was established. Other meetings have been conducted in the last year, London the 2nd of June and Geneve the 18th of June 2012.
    Last updated: 01 October 2014
  • 2012 Allergy School: Specific Allergy and Immunotherapy, El Escorial

    15 - 17 November 2012
    El Escorial, Spain

    Evidence based VIT and sting challenge
    Carmen Moreno, Hospital Universitario Reina Sofia, Cordoba, Spain

    Handling the procedures for Food Immunotherapy
    Montserrat Fernández Rivas, Hospital Clínico San Carlos, IdISSC, Madrid, Spain
    Pablo Rodríguez del Rio, Hospital Niño Jesús, Madrid, Spain

    How to start up immunotherapy practice
    O. Pfaar
    Center for Rhinology and Allergology, Wiesbaden,
    Dept. for Otorhinolaryngology, University-Hospital
    Mannheim, Germany

    Future of immunotherapy – basic and clinical research
    Mixing of allergen: how far can we go?

    C. Pereira
    Immuno-Allergy Department
    Coimbra University Hospital Center
    Medicine Faculty, Coimbra University Coimbra - Portugal

    More presentations will be available shortly.
    Last updated: 14 October 2014
  • 2012 Allergy School: Asthma Exacerbations - Risk Factors and Management, Tallinn
    2 - 5 August 2012
    Tallinn, Estonia


    Anti-IgE therapy on exacerbations
    Teet Pullerits
    Dept of Allergology
    Sahlgrenska University Hospital Gothenburg, Sweden

    Asthma exacerbations as phenotype determinants in children
    Ömer Kalayci
    Hacettepe University School of Medicine
    Ankara, Turkey

    Bronchial hyperresponsiveness – techniques & result interpretations
    Svetlana Sergejeva

    Definition, epidemiology and importance of asthma exacerbations
    Antoine Magnan
    Nantes University
    Service de Pneumologie
    Nantes, France

    Do inhaled steroids prevent asthma exacerbations?
    Jonathan Grigg
    Barts and the London School of Medicine
    London, UK

    Drugs used for cardiovascular disorders and risk for asthma exacerbations
    Pascal Demoly
    Allergy Unit - Department of Pulmonology
    University Hospital of Montpellier
    Hôpital Arnaud de Villeneuve - INSERM U657
    Montpellier, France

    Environmental associates of asthma exacerbations
    Adnan Custovic
    Professor of Allergy
    University of Manchester, UK

    Industrial and urban pollution
    Jonathan Grigg
    Barts and the London School of Medicine
    London, UK

    Interactions between viruses and atopy in asthma exacerbations
    Adnan Custovic
    Professor of Allergy
    University of Manchester, UK

    Asthma: Questionnaires in real life
    Pascal Demoly
    Allergy Unit - Department of Pulmonology
    University Hospital of Montpellier
    Hôpital Arnaud de Villeneuve - INSERM U657
    Montpellier, France

    Role of asthma severity and asthma control in asthma exacerbations – implications for treatment

    Alan Altraja
    Department of Pulmonary Medicine University of Tartu
    Estonia

    Severe asthma in children
    Sejal Saglani
    Clinical Senior Lecturer Respiratory Paediatrics
    Imperial College London, UK

    The role of macrolides
    Teet Pullerits
    Dept of Allergology
    Sahlgrenska University Hospital Gothenburg, Sweden

    Treatment of asthma exacerbations in children
    Sejal Saglani
    Clinical Senior Lecturer Respiratory Paediatrics
    Imperial College London, UK

    Use of biomarkers in predicting asthma exacerbations
    Alan Altraja
    Department of Pulmonary Medicine University of Tartu
    Estonia
    Last updated: 14 October 2014
  • 2012 Allergy School: From Skin to Lung – From Theory to Patients, Davos
  • 2008 EAACI Congress, Barcelona
    XXVII EAACI Congress
    7 - 11 June 2008
    Bracelona, Spain



    Quality Controls in Allergy
    Alistair Crockard
    Royal Hospitals
    Belfast, Northern Ireland


    Rational application of flow cytometry in allergy
    Didier Ebo
    Immunology – Allergology – Rheumatology
    University of Antwerp, Belgium


    Tips on writing a manuscript for peer-review
    Stephen Durham
    Section Allergy and Clinical Immunology
    NHLI, Imperial College London, UK


    Co-morbidities
    Jean Bousquet
    Editor of ALLERGY
    Professor of Respiratory Medicine
    Montpellier University
    Chairman of the Global Alliance against Chronic Respiratory Diseases (GARD)


    Making most of your Abstract, Poster and Oral Presentation
    Prof AJ Frew
    Brighton & Sussex Medical School


    From 0 to 100 in 8 seconds: How to succesfully improve your career
    Prof David Gronenberg
    Institute of Occupational Medicine
    Charité – Universitätsmedizin Berlin


    How can we prevent
    Prof Ulrich Wahn
    Department of Pediatric,
    Pneumology & Immunology


    When did it start
    Prof Thomas Platts-Mills

    Why Immunotherapy Fails
    Prof Stephen Durham


    Last updated: 14 October 2014

Contact us

Tab Articles

    Archive

    • EAACI Treasurer

      Marek Kowalski

      Last updated: 13 November 2014
    • Treatment can lead you to gold!

      Athletes who suffer from asthma or allergies and are about to participate in the 2008 Beijing Olympic Games, have the same chances for success with athletes that are not facing the same problem.

      Last updated: 13 November 2014
    • Mediterranean diet may protect kids from hay fever

      1807A Mediterranean-type diet may protect children from developing asthma and allergic rhinitis, which is largely known as hay fever.

      A recent research published in Allergy Journal, the official Journal of the EAACI, reports on the evidence of the additional benefits of healthy dietary habits to a healthy diet among children. Diet during pregnancy and childhood is thought to play an important role in children's asthma risk. In the current study, researchers examined the association between both children's diet and their mother's diet during pregnancy and the development of asthma and allergic rhinitis in a random sample of 1,476 children aged 6 to 7 years old.

      Among children, greater adherence in the previous year to a Mediterranean diet that it was high in vegetables, fruits and nuts, legumes, fish and cereals and low in dairy products, meat, junk food and fat, was associated with less asthma, wheezing, allergic rhinitis, sneezing and itchy-watery eyes.

      The researchers did not find an association between consumption of a Mediterranean diet during pregnancy and reduced risk of asthma or allergic rhinitis in children.

      According to the researchers, the suggestion that a Mediterranean diet may protect against asthma is biologically plausible. This type of diet is rich in antioxidants that may protect the lung and airway from oxidative damage. It is also rich in fish, a good source of omega-3 fatty acids and light in omega-6 fatty acids. This ratio of omega-3 to omega-6 fatty acids has been shown to reduce harmful levels of pro-inflammatory proteins, which are often increased in asthma sufferers.

      Source
      ALLERGY Journal, September 2008

      Last updated: 24 June 2016
    • Treatment can lead athletes to high achievements and safeguard fair competition

      Just a few months ahead of the Beijing 2008 Olympic Games and the European Football Cup, top experts on Allergy and Asthma from Europe and the US, gathered in Barcelona, in order to evaluate and talk on the dangers as well as the possibilities of athletes

      Last updated: 13 November 2014
    • Hospitals Put Allergy Patients at Risk
      Patients are being put at risk because some hospital doctors are not always following warning procedures over known drug allergies
      Last updated: 13 November 2014
    • Link between paracetamol use and asthma in European adults

      A link between paracetamol use and asthma in European adults was confirmed in GA²LEN study.

      Last updated: 13 November 2014
    • Allergies, Asthma and Wealth
      Children in richer nations are more likely to have allergy-related asthma than their counterparts in poorer nations
      Last updated: 13 November 2014
    • Transnational Research on the topic of allergic rhinitis

      A survey carried out by scientists in Germany, France, Italy, Spain and the U.K

       

       

      Last updated: 13 November 2014
    • Parental-reported drug allergy in 6- to 9-year-old urban schoolchildren

      Review article on epidemiologic studies about the prevalence of adverse drug reactions in children are scarce compared to reports in adults.

       

      Last updated: 13 November 2014
    • Food allergy prevention and management Asthma and Immunology

      Important research findings may impact diet restrictions of food allergic patients.

       

       

      Last updated: 13 November 2014
    • Whole Grains and Fish May Decrease Asthma Risk in Children

      A recent study in Dutch children has found that increasing intakes of fish and whole grains may help with asthma, especially in children.

       

      Last updated: 13 November 2014
    • XXVII EAACI Congress in Barcelona

      Under the slogan “Clinical Features of Allergy: From Pediatrics to Geriatrics” the XXVII EAACI Congress is up and running in Barcelona, the capital of Catalonia, from 07-11 June 2008.

      Last updated: 13 November 2014
    • World Asthma Day May 6th / Beijing Olympic Games

      Asthma & Sports: a mighty co-existence

      Last updated: 13 November 2014
    • Sport and asthma: GA²LEN researchers follow European Olympic athletes to Beijing

      Ten centres of GA²LEN will be following athletes selected for the Olympic Games 2008 to assess the prevalence and diagnosis rates of asthma and allergies.

      Last updated: 13 November 2014
    • Individualised treatments are the only efficient way to tackle with asthma

      Individualised treatments are the only efficient way to halt asthma`s advance.

       

      Last updated: 13 November 2014
    • NHS fails children with eczema

      Children with eczema in the UK are not getting the medical treatment they deserve as their parents use herbal medicines that may sometimes do more harm than good.

       

      Last updated: 13 November 2014
    • Europe and US together against childhood asthma

      The two major scientific organizations in the field of asthma, EAACI and AAAAI have reached consensus on optimal strategies to tackle asthma in childhood.

      Last updated: 13 November 2014
    • Announcement IPAC

      18 and 20 October 2007 Guincho, Portugal

      Last updated: 13 November 2014
    • Seasonal allergy in Texas

      The upcoming fall season could be the worst in decades for allergic people in Texas

      Last updated: 13 November 2014

    Static

    • Member Login
      Locked

      MEMBERS LOGIN

      Please enter your EAACI Membership details to login.
      If you forgot your username or password please click here.
      Member

      BECOME A MEMBER

      Please click below to submit for becoming an EAACI Member.
      You will be asked to fill up a Membership application form.
      Membership Fees
      Annual Fee EUR 150
      Annual Fee - Junior Members (≤35 years old) FREE
      50% reduction for members from countries with a GNP of less than USD 10,000 EUR 75
      EAACI/AAAAI Dual Membership (-20%) EUR 120
      EAACI/ACAAI Dual Membership (-20%) EUR 120
      EAACI/European Respiratory Society Dual Membership (-15%) EUR 128
      EAACI/European Rhinologic Society Dual Membership (-10%) EUR 135
      EAACI Allied Health Interest Group Members EUR 75
      Benefit

      BENEFITS

      memberlogin subscription Subscription
      to EAACI journals; Allergy, Pediatric Allergy and Immunology (PAI) and EAACI Newsletter
      memberlogin discounts Discounts
      on registration fees for EAACI Congresses, Focused Meetings, Schools and EAACI/UEMS Examinations and publications fees for Clinical and Translationnal Allergy (CTA)
      memberlogin free Free membership
      for all Junior Members (≤ 35 years old)
      memberlogin credits CME Credits
      for all out activities and events. Also valid in the USA and Canada due to a reciprocal agreement between UEMS, AMA and the Royal College of Physicians and Surgeons of Canada
        Sponsorhip
      of Clinical and Research Fellowships
      Last updated: 30 May 2016
    • Congress Login
      Last updated: 30 May 2016

    Disclaimer

    • Nestlé Health Science Disclaimer
      All content contained on this website are those of the editor and are independent of Nestlé Health Science.
      Last updated: 05 April 2016
    • EAACI WEB DISCLAIMER
      All materials provided by this Web site are intended for educational, communication and information purposes only and are not intended to replace or constitute medical advice or treatments.

      The EAACI intends that the information contained in this site to be accurate. Public education and information materials contained in this site have been reviewed and approved by the site's web editors or the EAACI Web Management Committee. However, due to error occurrence, EAACI disclaims any warranty of any kind, whether express or implied, as to any matter whatsoever relating to this servsiice. Under no circumstances, shall the EAACI be liable for any indirect, special, incidental or consequential damages arising out of reliance on any content of the web site contained herein.

      EAACI does not assume and hereby disclaims any and all liability to an entity for any claims, damages, liability or other loss including, without limitation, any liability for damage resulting from reliance on this service or from the posting of any content or material by any third party. No material included in this site shall be deemed to present necessarily the best method or procedure with respect to a matter discussed on this service; rather, any such material shall be acknowledged as the approach or opinion of the discussant.

      PRIVACY POLICY

      Privacy policy for the websites of the European Academy of Allergy and Clinical Immunology (EAACI)
      EAACI is committed to protecting your online privacy. This policy governs all pages hosted by EAACI, including the Allergynews.com website and any other website it will create in the future. It does not apply to pages hosted by other organisations, including National Societies of Allergy and Clinical Immunology, which have their own privacy policies.

      EAACI uses the information it collects about you to better understand how its website is used, to send information on EAACI you have requested or that may be considered of interest to you, to process your membership application and to render services you have ordered or which are included in your membership.

      To understand how your personal information will be treated, please read the following policy. This policy may change from time to time so please refer to it periodically.

      What identifiable information is collected from you?
      The type and amount of information received and stored by EAACI depends on how you use the website. You can access most EAACI pages without stating who you are and without revealing any personal information, except in the case of online membership applications or in the case you want to access the "Members Only Area" of the website.

      EAACI does not collect information identifying you personally (such as your name, address, phone number or e-mail address) unless that information is voluntarily disclosed. There are instances where EAACI requests information that does identify you personally for the purpose of providing you with specific services or of corresponding with you. Information that you supply in this way will not be shared with any third party except where needed to provide a requested service or required by law.

      How does EAACI use the information?
      EAACI does not distribute, sell or rent user information to anyone. EAACI uses the information collected about you to improve its understanding of web visitors, to send information that you have requested or that may be considered of interest to you, to process your membership application and to render services you've ordered or which are included in your membership. Some information identifying EAACI members is forwarded to third parties for purely technical and administrative processing (e.g. to Wiley Publishing to send out Allergy and Pediatric Allergy and Immunology (PAI) and the Newsletter). These parties are not authorized to distribute, sell or rent user information.

      With whom may EAACI share the information?
      EAACI will not disclose any information identifying you personally, except with your prior permission or where required by law.

      What choices are available to you regarding collection, use and distribution of the information?
      Any information on new EAACI products that you registered to receive will be sent to you electronically or by other means. EAACI may also send you unsolicited e-mail messages it feels may be of interest to you. You can indicate that you do not wish to receive the mail messages by sending an e-mail to info@eaaci.org and you will be removed from the recipients' list.

      How can you access, update or delete the information?
      EAACI takes very seriously the accuracy of the information it holds on you. If you change your e-mail address or discover inaccurate information, or if you wish to unsubscribe, please send an e-mail message to info@eaaci.org. Members are invited to regularly update their profile in the "Members Only Area" of the website.

      How does EAACI treat your personal information?
      EAACI ensures to the best of its ability that any personal information you provide is secure on its systems. However, it cannot guarantee that submitting information over the Internet is 100% secure. As a result, EAACI does not confirm or warrant the security of personal information submitted; you do so at your own risk.

      Automatically collected information

      Cookies

      Like many other websites, the EAACI site uses cookies in order to provide you with a more personalised web experience.

      A cookie is a text-only string of information that is created and stored on your computer by your browser. It contains information about your visit that your browser uses to personalise certain pages or elements. For statistical analysis purposes, a cookie may also be used to pass a randomly generated and anonymous unique number to our servers. Cookies cannot be used by themselves to identify you. A cookie will typically contain the name of the domain from which the cookie has come, the "lifetime" of the cookie, and a value, usually a text value or a randomly generated unique number.

      If you do not wish to receive cookies, you can easily modify your browser to reject all cookies or to notify you whenever one is about to be placed on your computer. However, if cookies are not accepted you may not be able to use all the interactive features of the EAACI website. You are therefore encouraged to allow cookies in order to enjoy the EAACI site fully.

      Log files

      Most standard web servers, including EAACI's, use log files, which record information such as:

      • service provider IP addresses;
      • browser versions;
      • referring web sites;
      • search terms used;
      • average number of pages requested;
      • average duration of visit;
      • total visitor traffic;
      • information gathered for aggregate use.

      Disclaimer

      This site contains hypertext links to other sites. EAACI.org is not responsible for any third-party content or privacy practices accessible through this website. We do not endorse any of the companies or opinions listed in or linked to or from the website. We also do not accept or host any advertising.


      PROPRIETARY NOTICES

      "THE EUROPEAN ACADEMY OF ALLERGOLOGY AND CLINICAL IMMUNOLOGY", "EAACI", and the EAACI logo are trademarks of The European Academy of Allergology and Clinical Immunology. Use of these marks in commerce is prohibited by law except by obtaining the expressed written permission of the EAACI Web Committee.

      Copyrights to the materials posted in this site are owned solely by the EAACI, except for materials which are created by others (or the copyright to which is otherwise owned by others) and for which a copyright notice is posted adjacent to such content or materials. The copyright to each item of material created or otherwise owned by another is owned by such creator or other owner. None of the materials included in this site shall be reproduced in any form without the expressed written permission of the EAACI, the creator or other owner, as the case may be. In this regard, the graphic images and layout of this site are the exclusive property of the EAACI and may not be copied, distributed or displayed except using an HTML browser or as otherwise stated herein, without the expressed written permission of the EAACI Web Committee.

      Permission is hereby granted to (1) print copies of the materials for which the EAACI holds the copyright ("EAACI content") and to otherwise display the EAACI content, (2) include a link to the Uniform Resource Locator (URL) of this site to HTML documents, and (3) to use the EAACI content subject to the following conditions:
      Such use is by computer using HTML browser software; Such use is solely for personal and noncommercial use and only for informational and/or educational purposes; Users shall not make any profit from the EAACI material in any way (i.e., by selling or charging for same) unless the expressed written permission of the EAACI is first obtained;

      Any copying or quoting of the EAACI content shall be accompanied by the following copyright notice: "© Copyright 2008 The European Academy of Allergology and Clinical Immunology. All rights reserved."

      Except as stated herein, no portion of the materials included in this site may be reproduced or transmitted in any form by any means, whether by electronic, photocopying, recording or otherwise, without the written permission of the EAACI.

      Address inquiries regarding the use of the EAACI trademarks, logos and copyrights or the trademarks, logos and copyrights of third parties which are contained in this site to:

      EAACI Headquarters
      Hagenholzstrasse 111
      3rd Floor
      8050 Zurich
      Switzerland
      Telephone: +41 44 205 55 33
      Fax: +41 44 205 55 39 P.O. Box 24140
      Email:info@eaaci.org


      EAACI RESOURCES

      Disclaimer and Proprietary Notices
      This service is intended for use only by medical professionals and academics. The materials and other information provided by this service are for general educational, communication and information purposes only and are neither designed nor intended to replace nor constitute the giving of case specific or other medical advice, treatments or diagnosis. Under no circumstances shall any information, content or material posted on this service or any other communication thereunder be deemed to constitute the giving of medical advice, treatment or diagnosis. The user of this service shall be solely responsible for whether or how to interpret, apply or otherwise use any information in any specific case.

      No information cited under Resources shall be deemed to present the only or necessarily the best method or procedure with respect to a matter discussed on this service; rather, the user acknowledges that any such information or material is acknowledged as the approach or opinion of the discussant. The user takes all risks of using the material included in this service.

      EAACI does not assume and it hereby disclaims any and all liability to any person or entity for any claims, damages, liability or other loss including, without limitation, any liability for injury or other damage resulting from reliance on this service or from the posting or transmission of any information, content or material on this service by EAACI, or any third party. By using this service the user releases EAACI and its directors, officers, members, or agents from and against any and all such liability.



      EAACI WEBCASTS

      Disclaimer and Proprietary Notices
      By viewing the EAACI Web Casts, the user agrees to the following terms ("Terms") governing use of the Web Casts, plus any additional terms and conditions posted at specific portions of the web site. Access to the Web Casts and all related pages is conditioned upon the user's acceptance of the following terms:
      Access. The EAACI grants all users to a non-exclusive, revocable license to use the materials and information on the Web Casts solely for professional practice in accordance with the Terms herein. All users are responsible for their acts or omissions in the use of the Web Casts and for any damages incurred by them or anyone else as a result thereof.
      Purpose. The Web Casts and their content are being provided for educational and informational purposes only, and are not intended to be a substitute for an independent medical judgment or constitute medical advice or treatment in any way. The content posted on the Web Casts is not intended to serve as the primary basis for making professional medical decisions. As with all clinical reference resources, the content on the Web Casts reflects medical science, protocols and/or procedures at the time of its development, but the content should be used with the clear understanding that continued research or practice may result in new knowledge or recommendations. Therefore, all users should cross check the information given in the Web Casts with other sources before undertaking any treatment or otherwise taking any actions related to or in reliance on such information. The user's reliance upon any content within the Web Casts is solely at their own risk.
      Damages. Under no circumstances will EAACI be responsible or liable for any damages of any kind or nature that result, or relate in any way to the use of this site or any content herein, including, without limitation, any compensatory, indirect, incidental, consequential, damages.


      PHOTOS, GRAPHICS & TEMPLATES

      To visually demonstrate the physiology of allergic diseases and asthma in Europe and/or support any material posted in the web site, the EAACI has developed allergy and asthma graphics and templates which may serve as visuals to compliment the speaker's presentation in the EAACI meetings. For use of any of the above features, kindly attribute all images as follows:

      "Source: The European Academy of Allergology and Clinical Immunology."
      Last updated: 03 June 2016

    E-Bulletin

      Media

        Activities

          Organisation

            sections

            • Introduction Sections
              Diseases mediated by allergic and immunological mechanisms can affect many different organs and may present problems to a wide variety of physicians in primary and secondary care. In order to improve information exchange and collaboration between specialists and scientists both within and outside the EAACI, the Academy has established the EAACI Sections on Asthma, Dermatolofy, ENT, Immunology and Pediatrics. The sections are represented in the Executive Committee by their chairs and Programme Committee, and have the opportunity to propose task forces as well as joint sessions with appropriate specialists societies.

              All EAACI members are welcome to be part of one or more of the Sections or Interest Groups with voting rights. To do so, you need to go to your profile and choose Section(s) or/and Interest Group(s) you want to be part of.


              EAACI Asthma Section bannerEAACI Dermatology Section bannerEAACI ENT Section banner
              EAACI Immunology Section bannerEAACI Pediatrics Section banner
              Last updated: 30 June 2016

            Juniors

            Resources

            • Research Seminars
              This page is under construction.
              Last updated: 30 May 2016
            • CTA-JM Quiz

              Win one (or both) of the comprehension-based CTA-JM Quizzes related to CTA publications and publish your manuscript for free in the CTA Journal.
              Mechanisms in allergen-specific immunotherapy
              Fungal allergy in asthma

              :EAACI Junior Members and Affiliates Mentorship Programme (MP) aims to promote ongoing educational and professional opportunities for young scientists and enhancing the JMAs capacity as a professional. The MP is expected to improve the knowledge transfer from experienced professionals to juniors, as well as increasing the JMAs' appreciation of, and orientation within, the field. Normal 0 false false false EN-AU X-NONE X-NONE
              Last updated: 15 June 2016

            IGs

            • Introduction Interest Groups
              The Interest Groups represent an area of more specific interest within allergology. Additionally, Interest Groups provide a focus for scientists and clinicians interested in particular aspects of allergic diseases. The Interest Group forms a focus for discussion at the Academy's meetings, provides input to the scientific programme, and can make proposals for the task forces.

              All EAACI members are welcome to be part of one or more of the Sections or Interest Groups with voting rights. To do so, you need to go to your profile and choose Section(s) or/and Interest Group(s) you want to be part of. 

              Aerobiology PollutionAllergy Asthma SportsAllergy DiagnosisAllied HealthBiologicalsComparative and Veterinary AllergologyDrug AllergyEosinophilic EsophagitisEpidemiologyFood AllergyImmunotherapyInfection AllergyInsect Venom HypersensitivityOccupational AllergyOcular AllergyOMICS and Systems MedicinePrimary CarePrimary Immunodeficiency
              Last updated: 30 June 2016

            Homepage Deadlines

            Homepage Congresses

            Outreach

              Upcoming events

              Homepage Updates

              Questions Patients

              • Question 1
                Have you got asthma?
                Last updated: 06 June 2014
              • Question 2
                Is your child allergic to milk?
                Last updated: 06 June 2014
              • Question 3
                Have you been recommended vaccines?
                Last updated: 06 June 2014
              • Question 4
                Tired of sneezing all the time?
                Last updated: 06 June 2014
              • Question 6
                Don't know how to use inhalers?
                Last updated: 06 June 2014
              • Question 5
                Is your itchy skin killing you?
                Last updated: 06 June 2014

              Uncategorized

              • test chris 2
                {gallery}photos/2014/WSBrasov/{/gallery}
                Last updated: 06 October 2014
              • Past Task Forces
                -. Task Force on “Standardization of (Primary) Clinical Outcomes for Clinical Trials in AIT

                TF-Coordinators: Oliver Pfaar and Sabina Rak

                Start-date: 2011, current status: ongoing

                Rationale: Generally accepted and authoritative national and international guidelines are still lacking with respect to the assessment of the therapeutic effects of AIT by using clearly-defined symptom- and medication-scores. Therefore, the aim of the task-force will be to propose a position statement clearly defining how symptoms and medications should be assessed, analyzed and adequately weighted in prospective clinical trials on both SLIT and SCIT. Current status: EAACI-Position Paper in progress

                -. Project "Semantics in SIT and MedDRA terminology for adverse reactions due to SIT" Coordinator: Pascal Demoly and Moises Calderon

                Start date: 2011

                Finish date: 2012

                Rationale: Current semantic use to characterize allergen immunotherapy and terminology for adverse reactions is heterogeneous depending on the countries and/or the scientific societies.

                Main objective:
                To create a common language for all audiences regarding immunotherapy and identify semantic keys to reinforce the impact of communication on allergy immunotherapy. To create a harmonised MedDRA based terminology for the report of adverse reactions after SIT in a real life setting.

                -. Task force on “Contraindications for AIT”

                Coordinator:
                Constantinos Pitsios

                Start date: 2011

                Finish date: 2013

                Rationale: Despite the large number of papers published on SCIT and SLIT, there is still no common agreement on the “contra-indications” for SIT.

                Main objective: To collect and compare clinical data on the effect of Allergen Immunotherapy on conditions and diseases that are currently considered as contraindications.
                A systematic literature search has been performed to re-assess AIT contraindications and adapt them to the current situation of different diseases, co-morbidities and certain drugs. Current status: A Consensus Meeting has taken place on May 2013 and the Task Force Report - Position paper is in progress. An international survey (CONSIT) regarding the opinion of allergologists on AIT's contraindications has been performed and is soon going to be published.

                Last updated: 12 February 2015
              • rtest6
                test6333 rer testet testtt asdasd sdsdf
                Last updated: 06 October 2014
              • test5
                test5
                Last updated: 06 October 2014
              • Not Found

                Page Not Found :(

                Sorry, but the page you were trying to view does not exist.

                Please use the sitemap in case you can not find what you are looking for

                Last updated: 20 November 2014

              Image Gallery

              Allergy Schools Travel Grants

              • Allergy School on Allergen Immunotherapy (AIT) Denmark 2016 - winners

                Travel Grant and Poster Prize winners

                Poster Prize winners:

                Monica Rodriguez Gonzalez, Mexico
                Abstract: Clinical And Sensitization Profile Of Children Recieving Allergy Immunotherapy In Mexico City.
                David Alejandro Mendoza-Hernandez, Monica Rodriguez-Gonzalez, Maria Socorro Orozco-Martinez
                NATIONAL INSTITUTE OF PEDIATRICS, Mexico City, Mexico

                Carla Mastrorilli, Italy
                Abstract: Long-Term Assessment Of Allergen Specific Immunotherapy In Children
                Carla Mastrorilli, Vera Raggi, Marilena Garrubba, Dora Di Mauro, Carlo Caffarelli
                Pediatric Dept, Department of Clinical and Experimental Medicine, Azienda Ospedaliera-Universitaria, University of Parma, Parma, Italy

                Travel Grant winners:

                Byrthe Jorga Petra Ruth Vos, The Netherlands
                Abstract: Initiating Yellow Jacket Venom Immunotherapy With A 100 Microgram Dose Of Venom.
                Byrthe Jorga Petra Ruth Vos, Anthony Ewoud Jan Dubois, Joanna (Hanneke) Nicola Gertrude Oude Elberink

                Nurul Asma Abdullah, Malaysia
                Abstract: Lignosus Rhinocerus Extract Suppresses Airway Inflammation And Regulates Treg Imbalance In The Ovalbumin-Induced Asthmatic Model.
                Nurul Asma Abdullah , Johnathan Malagobadan, Gan Siew Hua, Faezahtul Arbaeyah Husain, Wan Ezumi Mohd Fuad

                Elena Kashirina, Russia
                Abstract: INDUCTION OF HUMORAL IMMUNE RESPONSE BY ALLERGENS CAPSULATED INTO POLYMERIC CHITOSAN- ALGINATE NANOPARTICLES
                Elena Kashirina, Elena Svirshchevskaya, Tatiana Shcherbinina

                Filipa Matos Semedo, Portugal
                Abstract: Mite Component Resolved Diagnosis And Tailored Specific Immunotherapy
                Filipa Matos Semedo, Elza Tomaz, Ana Paula Pires, Fernando Pineda, Filipe Inácio

                Heidi R. Myrse, Norway
                Abstract: High Affinity Interaction Between An Ara H 2-FGL2 Fusion Protein And The Inhibitory Receptor FcgRIIb, As Meassured By Thermophoresis.
                Heidi R. Myrset, Maaike M.B.W. Dooper, Christin Plassen, Eliann Egaas

                Last updated: 12 April 2016
              • Food Allergy Training Course - winners

                Travel Grant and Poster Prize winners

                Poster Prize winner:

                Joana Gomes Belo, Portugal
                Abstract: Clinical features of Pru p 3 sensitized patients attending an outpatient Immunoallergology Department in Lisbon
                Joana Gomes Belo, Elena Finelli, Nicole Pinto, Pedro Martins
                Immunoallergy Intern of Dona Estefania Hospital, Lisbon, Portugal


                Travel Grant winners

                Michael Rudenko, United Kingdom
                Abstract: Onset of milk allergy in an adult with no history of allergy as a child                   
                Michael Rudenko, Pavaladurai Vijayadurai

                Mariana Pinto, Portugal
                Abstract: Growth and body composition patterns in children with food allergy                 
                Mariana Pinto, Patrícia Padrão, André Moreira, Pedro Moreira, Joana Madureira, Eduardo Oliveira Fernandes

                Christine Breynaert, Belgium
                Abstract: LTP as a hidden allergen in food dependent exercise induced anaphylaxis: two case reports                  
                Christine Breynaert, Rik Schrijvers, Anne-Marie Kochuyt, Jan Ceuppens

                Laura Martin-Pedraza, Spain
                Abstract: Sola l 7, a different member of a protein family (non-specific lipid transfer protein), responsible for tissue-specific sensitization in tomato allergic patients.                             
                Laura Martin-Pedraza, Miguel González, Pablo San-Segundo, Juan Carlos López-Rodríguez, Cristina Bueno Díaz, Guillermo Solís Fernández, Eva Batanero, Rodrigo Barderas Manchado, Miguel Blanca, Cristobalina Mayorga, Mayte Villalba Díaz
                Last updated: 02 October 2015
              • Molecular and Laboratory Asthma: A course for the practicing clinician

                Travel Grant and Poster Prize winners

                Sehra Birgül Batmay, Turkey
                Abstract title: Impulse Oscillometry In Acute And Stable Asthmatic Children: A Comparison With Spirometry

                Žavbi Mateja, Slovenia
                Abstract title: Association Between 17q12-17q21.1 Polymorphisms, Haplotypes And Adult Asthma

                Inês Mota, Portugal
                Abstract title: Time Course Of Exercise-induced Bronchoconstriction In Children

                Olga Semernik, Russia
                Abstract title: Concentration Of Vascular Endothelial Growth Factor In The Exacerbation Of Asthma In Children

                Mariam Shahid, Pakistan
                Abstract title: Urbanization Triggers Asthma In 'C' Allele Carriers For Rs12603332

                Poster prize winner
                Žavbi Mateja, Slovenia
                Abstract title: Association Between 17q12-17q21.1 Polymorphisms, Haplotypes And Adult Asthma

                Inês Mota, Portugal
                Abstract title: Time Course Of Exercise-induced Bronchoconstriction In Children
                Last updated: 21 April 2015
              • Winter School on Basic Immunology Research in Allergy and Clinical Immunology- winners

                Travel Grant and Poster Prize winners

                Cristina Cirauqui, Spain
                Abstract title: The Role Of Dendritic Cells In The Immunological Mechanisms Of Action Of Polyvalent Bacterial Preparations As Novel Vaccines To Prevent Recurrent Respiratory Tract Infections

                 Marcin Fraczek, UK
                Abstract title: Microbiome Molecular Identification And Regulatory T Cells / TH17 Immune Responses In Lung Of ABPA, SAFS And Severe Asthma Patients

                Dhiren Patel, UK
                Abstract title: The Dual Role Of Leukotriene A4 Hydrolase In Allergic Airway Disease

                Mahesh Raundhal, USA
                Abstract title: IFN-<gamma> And IL-17A Drive Distinct Airway Changes In A Murine Model Of Steroid-unresponsive Severe Asthma

                Baos Muñiz Selene, Spain
                Abstract title: New Biomarkers Of Asthma Severity?

                Tatiana Shcherbinina, Russia
                Abstract title: Influence Of Polysaccharide Shell On Immunogenic Properties Of Protein Nanoparticles

                Gergely Toldi, Hungary
                Abstract title: B7 Costimulation And Intracellular Indoleamine 2,3-dioxygenase Expression In Umbilical Cord Blood And Adult Peripheral Blood

                Vasiliki Triantafyllia, Greece
                Abstract title: Study Of The Regulation Of Interferon-<lambda> Production By Dendritic Cells In Airway Inflammation

                Poster Prize Winners
                Stephan Loeser


                Last updated: 06 June 2015
              • Early Diagnosis and Treatment of Allergic Diseases in Childhood - winners

                Travel Grant and Poster Prize winners

                Foued Abdelaziz, Algeria
                Abstract title: A Sensitization Study Of Atopic Children In Constantine. A Retrospective Study Of 413 Children Between 2006 And 2009

                Francesca Cipriani, Italy
                Abstract title: Different Phenotypes Among Children With Atopic Dermatitis By FLG Gene Mutations: Preliminary Data

                Annalisa Di Coste, Italy
                Abstract title: Predictivity Of Clinical Efficacy Of Sublingual Immunotherapy Based On Patient's Molecular Pattern.

                Henrik Wegener Hallas, Denmark
                Abstract title: Lung Function Development In Asthmatic Children

                Hanna Knihtilä, Finland
                Abstract title: Small Airway Function Assessed By Impulse Oscillometry In Healthy And Symptomatic Preschool Children

                Kotryna Linauskiene, Lithuania
                Abstract title: Tennager And His Three Attemps Of Sublingual Allergen Specific Immunotherapy

                Poster prize winner
                Stefania Arasi, Italy
                Abstract title: Omalizumab Therapy For Solar Urticaria: A Case Report

                Francesca Cipriani, Italy
                Abstract title: Different Phenotypes Among Children With Atopic Dermatitis By FLG Gene Mutations: Preliminary Data

                Henrik Wegener Hallas, Denmark
                Abstract title: Lung Function Development In Asthmatic Children

                Vladyslava Barzylovych, Ukraine
                Abstract title: Modern Approaches to Rational Feeding in Children with High Risk of Allergic Diseases

                Last updated: 12 March 2015
              • Allergy School on Allergy Diagnosis in and beyond the skin - Travel Grant Winners
                Pavel Kolkhir
                Abstract 2426960
                Autologous Serum Skin Test And Autoimmune Biomarkers In Diagnosis Of Chronic Spontaneous Urticarial”

                Juan Manuel Leyva-Castillo
                Abstract 2424046
                Innate and adaptive recruitment of basophils in a thymic stromal lymphopoietin-induced atopic dermatitis mouse model
                Last updated: 21 October 2014
              • Allergy School on Allergic Reactions to Drugs – From Phenotype to Genotype - Travel Grant Winners
                Katinka Onodi-Nagy
                Abstract 2393415
                In Vitro And In Vivo Investigation Of Amoxicillin-Induced Exanthema In Patients With Infectious Mononucleosis

                Semra Demýr
                Abstract 2439644
                Clinical Analysis Of Nonsteroid Antiinflamatory Drugs Hypersensitive Patients: Atopy May Increase The Risk Of Additional Drug Allergy

                Nicolae Viorel Dumitrescu
                Abstract 2441445
                Research On Nsaids Types Involved In Hypersensitivity Reactions And The Safety Profile Of The Cox-2 Selective Nsaids In Patients With Chronic Urticarial
                Last updated: 21 October 2014
              • Allergy School on The place of "omics" in the diagnostic lab: Update on Allergy & Clinical - Travel Grant Winners
                Shanna Bastiaan-Net
                Abstract 2390583
                Differential Allergy To Prawn And Shrimp: A Case Of Epitope Specificity Or Difference In Allergens?

                Ewa Pniewska
                Abstract 2429013
                Taqman Low Density Array Cards As A Tool For Searching The Expression Profile Of Genes Involved In Airway Inflammatory Diseases

                Jan Remsik
                Abstract 2390353
                Changes In Th1/Th2 Ratio After Built-Up Phase Of Subcutaneous Allergen-Specific Immunotherapy”

                Dorota Kacprzak
                Abstract 2429633
                Microarray Studies As A Useful Tool For Identifying Genes Involved In Aspirin-Induced Asthma
                Last updated: 20 October 2014
              • Allergy School on Hymenoptera Venom - Travel Grant Winners
                Süleyman Tolga Yavuz
                Abstract 2283769
                Risk Factors For Side Effects During Venom Immunotherapy In Children With Hymenoptera Venom Allergy

                Martina Vachova
                Abstract 2303869
                Laboratory parameters in hymenoptera venom allergic patients during venom immunotherapy - 6 years study

                Dimitrios Mitsias
                Abstract 2305429
                Sting challenge proves the effectiveness of 50ìg dose in honey bee venom immunotherapy

                Ines Schwarz
                Abstract 2307491
                Does the sting localization play a role for the severity of symptoms in hymenoptera venom allergy?

                Danijela Bokanovic
                Abstract 2307520
                Negative predictive value of the basophil activation test in hymenoptera venom allergy

                Christoforos Koulias
                Abstract 2314912
                A modified rush venom immunotherapy protocol for subjects with underlying mast cell disease
                Last updated: 17 October 2014
              • Investigating allergic effects of environmental exposures - winners

                Travel Grant and Poster Prize winners

                Marta da Fonseca Gabriel, Spain
                Abstract title: Development Of A Phylogeny And Gene Encoding-based Tool For Detection Of Alt A 1 Allergen

                Teresa Stemeseder, Austria
                Abstract title: IgE Profiling Of 378 Non-selected Austrian School Children And Investigation Of Their Lifestyle

                Poster prize winner
                Peter Gajdos, Czech Republic
                Abstract title: Upper Respiratory Infections And Allergic Diseases In Ostrava

                Oral abstract prize winner
                Richard Sanya, Uganda
                Abstract title: Associations Between Helminth Infections And Atopy And Allergy-related Diseases In Island Communities In Uganda: Baseline Findings Of The Lake Victoria Island Intervention Study On Worms And Allergy
                Last updated: 16 October 2014
              • Allergy School on An Insight into Allergy and Allergen Immunotherapy - winners

                Travel Grant and Poster Prize winners

                Heidi Hofer, Austria
                Abstract title: MBC4: A hypoallergenic variant for treatment of birch pollen and associated food allergies towards apple and hazelnut

                Elena Kasche, Germany
                Abstract title: Immunogenicity, induction of allergen tolerance, safety, and clinical tolerability of increasing doses of GpASIT+TM administered subcutaneously to hay fever patients

                Alkerta Ibranji, Albania
                Abstract title: The role of allergy immunotherapy on asthma control in teenagers sensitized to house dust mites

                Sandra Viviana Olariu, Romania
                Abstract title: An unusual case associating meningioma and rare side effects to sublingual immunotherapy

                Gjustina Loloci, Albania
                Abstract title: Systemic adverse events a rare reaction to sublingual immunotherapy: A case report

                Pablo Rodriguez Del Rio, Greece
                Abstract title: Using AIT despite contraindications; CONtraindications to Specific ImmunoTherapy (CONSIT) Study

                Laura Hesse, Netherlands
                Abstract title: Subcutaneous and sublingual immunotherapy effectively suppress asthma manifestations in a mouse model of grass-pollen induced allergic asthma

                Huan Zhang, Sweden
                Abstract title: Sublingual immunotherapy alters expression of IL-4 and its soluble and membrane-bound receptors”
                Last updated: 16 October 2014

              Website past committies

              Latest Educational Resources

              PhARF Award 2015

              • PhARF Award 2015
                PhARF 2015 MilnerThe winner of the PhARF Award 2015 is Joshua David Milner, MD, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, US. It was announced at the Opening Ceremony of the EAACI Congress in Barcelona 6 June.
                 
                Dr Milner is an extraordinary young investigator, with an outstanding publication record whose exceptional originality and creativity has led to improved understanding of the genetics of atopic disease and pathophysiologic mechanisms revealed by genetic mutations. He has also identified potential therapeutic targets for mast cell diseases, which impact a variety of disorders.

                The winner of the PhARF Award 2015 is Joshua David Milner, MD, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, US. It was announced at the Opening Ceremony of the EAACI Congress in Barcelona 6 June.

                cid:image001.jpg@01D09F78.2F6144A0

                Dr Milner is an extraordinary young investigator, with an outstanding publication record whose exceptional originality and creativity has led to improved understanding of the genetics of atopic disease and pathophysiologic mechanisms revealed by genetic mutations. He has also identified potential therapeutic targets for mast cell diseases, which impact a variety of disorders.

                Last updated: 23 June 2015

              Upcoming congress

              Guidelines and Atlases homepage

              Monographs & User Guides

              Slide kits - Presentations